scispace - formally typeset
P

Pedro Brugada

Researcher at Maastricht University Medical Centre

Publications -  38
Citations -  10720

Pedro Brugada is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Sudden death & Ventricular tachycardia. The author has an hindex of 25, co-authored 38 publications receiving 10328 citations. Previous affiliations of Pedro Brugada include University of Pavia & University of Southern California.

Papers
More filters
Journal ArticleDOI

Brugada Syndrome: Report of the Second Consensus Conference Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association

TL;DR: The present report elaborates further on the diagnostic criteria and examines risk stratification schemes and device and pharmacological approaches to therapy on the basis of the available clinical and basic science data.
Journal ArticleDOI

Task Force on Sudden Cardiac Death of the European Society of Cardiology

TL;DR: The members of the Task Force on Sudden Death dedicate this paper to the memory of their former friend and colleague, Professor Ronald W. F. Campbell, who spent his life working in the field of sudden cardiac death, and the extent of the expanding knowledge in this field is described.
Journal ArticleDOI

Sudden death associated with short-QT syndrome linked to mutations in HERG.

TL;DR: The genetic basis for a new clinical entity characterized by sudden death and short-QT intervals in the ECG is described and a novel genetic and biophysical mechanism responsible for sudden death in infants, children, and young adults caused by mutations in KCNH2 is demonstrated.
Journal ArticleDOI

Sodium Channel Blockers Identify Risk for Sudden Death in Patients With ST-Segment Elevation and Right Bundle Branch Block but Structurally Normal Hearts

TL;DR: A similar incidence of potentially lethal arrhythmias in patients displaying transient versus persistent ST-segment elevation and right bundle branch block is demonstrated, as well as the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk.